Miraomics

Miraomics is a private, early-revenue biotechnology services company founded in 2018, focusing on the oncology and diagnostics sectors through computational analysis. The firm operates as a specialized consultancy, offering bioinformatics infrastructure, clinical biomarker discovery, and pipeline development support for therapeutic companies, leveraging over 20 years of combined industry experience. With a lean team likely under 50 employees, it positions itself as a strategic partner for biotechs and pharmas navigating IND/FDA submissions and complex multi-omic data. The company's success hinges on the growing demand for sophisticated data analysis in cell and gene therapy, though it faces competition from larger CROs and internal bioinformatics teams.

Expertise in multi-omics data integration, spatial transcriptomics analysis, and cell type annotation. Builds custom computational biology infrastructure and analytical pipelines for client projects, leveraging industry-standard and open-source tools.

Miraomics competes with large, full-service Contract Research Organizations (CROs) that offer bioinformatics as part of a suite, specialized bioinformatics CROs (e.g., Tempus Labs in oncology data, though much larger), and the internal bioinformatics departments of its potential biotech and pharma clients. Its differentiation lies in its boutique, therapeutic-area-focused approach (cell therapy/large molecules) and deep regulatory submission experience.